Skip to main
  1. Stocks
  2. Rezolute
  3. Forecast
RZLT

Rezolute (RZLT) Stock Forecast & Price Target

Rezolute (RZLT) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rezolute is supported by a favorable FDA regulatory signal for ersodetug in congenital hyperinsulinism, where the agency recommended a pre-BLA meeting after its review of Phase 3 sunRIZE data and did not request an additional trial, improving the perceived path to approval. The clinical case is strengthened by consistent evidence of hypoglycemia reduction, continued glycemic benefit in the open-label extension for 9 months to 2 years, and meaningful reductions in background standard-of-care use, suggesting durable activity across hyperinsulinism populations. In tumor-associated hyperinsulinism, management disclosed seven responders among the first eight evaluable patients in upLIFT, leaving the study two responses away from the approximate nine needed for success among sixteen patients and reinforcing confidence in a positive readout.

Bears say

Rezolute is facing a poor risk-reward profile because its lead program could be halted by unforeseen safety or tolerability issues, which would immediately undermine the value of its single clinical asset. Even if development continues, the company could still lose commercial relevance if more efficacious products enter the market and capture share, limiting the eventual return on its rare-disease strategy. On top of that, Rezolute may fail to secure the financing needed for additional studies or commercialization, creating a material funding risk that could prevent the asset from reaching approval or meaningful revenue generation.

Rezolute (RZLT) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rezolute and is not a guaranteed prediction by Public.com or investment advice.

Rezolute (RZLT) Analyst Forecast & Price Prediction

Get the latest Rezolute (RZLT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Rezolute (RZLT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rezolute (RZLT) Forecast

Analysts have given Rezolute (RZLT) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Rezolute (RZLT) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rezolute (RZLT)


Rezolute (RZLT) Analyst Forecast & Price Prediction

Get the latest Rezolute (RZLT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Rezolute (RZLT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover RZLT stock data and trends